Jeremy G. Chadwick, Chief Operating Officer at Kymera Therapeutics, Inc. (KYMR), sold 17,184 shares at $78.36 ($1.4M) on 2026-05-26, disclosed to the SEC on 2026-05-27.
Scheduled sale ($1.4M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $78.36 | 3,730 | $292K | 21.3% |
| 2 | $79.17 | 324 | $26K | 1.9% |
| 3 | $79.39 | 3,800 | $302K | 22.0% |
| 4 | $80.02 | 4,500 | $360K | 26.2% |
| 5 | $80.71 | 551 | $44K | 3.2% |
| 6 | $81.50 | 3,679 |
| $300K |
| 21.8% |
| 7 | $82.08 | 600 | $49K | 3.6% |
| Total | $79.92 avg | 17,184 | $1.4M | 100% |
| Filing → |
| KYMR | SELL | 2026-04-01 | $1.9M | — | Filing → |
| KYMR | SELL | 2026-03-25 | $18.0M | — | Filing → |
| KYMR | SELL | 2026-03-11 | $4.3M | — | Filing → |